MTOR and renal carcinoma: To study the effect of currently used TKI and mTOR inhibitors in renal cancer treatment, HEK293, Caki-1, 786-O, and A-498 cell lines were treated with three TKI (Axitinib, Cabozantinib, and Lenvatinib) or with two mTOR inhibitors (Everolimus and Temsirolimus).